EUVIMEDEUVIMED entdecken
Open Access · CC BY 2.0

Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway

Guochao Song, Fengyi Weng, Bin Zou, Jing Zhao, Jingyi Jin, Dongming Yan, Kai Huang, Xin Sun, Chenghai Liu, Yiyang Hu, Yue Li iD, Furong Qiu iD

Clinical Science · 13.04.2023 · 137 (7) · 561-577

DOI: 10.1042/cs20220674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, online erschienen am 13.04.2023. Verfasst von Guochao Song und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road,…. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Cholestasis. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholestasis is a pathophysiologic syndrome with limited therapeutic options. Tauroursodeoxycholic acid (TUDCA) has been employed to treat hepatobiliary disorders and is as effective as UDCA in alleviating cholestatic liver disease in clinical trials. Until now, TUDCA’s mechanism of action toward cholestasis remains unclear. In the present study, cholestasis was induced with a cholic acid (CA)-supplemented diet or α-naphthyl isothiocyanate (ANIT) gavage in wild-type and Farnesoid X Receptor (FXR) deficient mice, using obeticholic acid (OCA) as control. The effects of TUDCA on liver histological changes, transaminase level, bile acid composition, hepatocyte death, expression of Fxr and nuclear factor erythroid 2-related factor 2 (Nrf2) and target genes, as well as apoptotic signaling pathways, were investigated. Treating CA-fed mice with TUDCA markedly alleviated liver injury, attenuated bile acids retention in liver and plasma, increased Fxr and Nrf2 nuclear levels and modulated the expression of targets regulating synthesis and transportation of bile acids, including BSEP, MRP2, NTCP and CYP7A1. TUDCA, but not OCA, activated Nrf2 signaling and exerted protective effects against cholestatic liver injury in Fxr−/− mice fed with CA. Furthermore, in both mice with CA- and ANIT-induced cholestasis, TUDCA decreased expression of GRP78 and CCAAT/enhancer-binding protein homologous protein (CHOP), reduced death receptor 5 (DR5) transcription, caspase-8 activation, and BID cleavage, and subsequently inhibited activation of executioner caspases and apoptosis in liver. We confirmed that TUDCA protected against cholestatic liver injury by alleviating BAs burden of dually activating hepatic Fxr and Nrf2. Moreover, inhibiting CHOP-DR5-caspase-8 pathway contributed to the anti-apoptotic effect of TUDCA in cholestasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2CholestasisMiceAnimalsCaspase 8LiverBile Acids and SaltsTaurochenodeoxycholic Acid

Stichwörter der Autor:innen

Anti-apoptosisCCAAT/enhancer-binding protein homologous proteinCholestasisFarnesoid X ReceptorNuclear factor erythroid 2-related factor 2Tauroursodeoxycholic acid

Substanzen

NF-E2-Related Factor 2Caspase 8Bile Acids and SaltsursodoxicoltaurineTaurochenodeoxycholic Acid

Autor:innen und Institutionen

  • Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New District, Shanghai 201213, China.
  • Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New District, Shanghai 201213, China.
  • Institute of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Pudong New District, Shanghai 201213, China.

ORCID-Profile: Yue Li, Furong Qiu

Zitieren

APA

Song, G., Weng, F., Zou, B., Zhao, J., Jin, J., Yan, D., Huang, K., Sun, X., Liu, C., Hu, Y., Li, Y., & Qiu, F. (2023). Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway. Clinical Science, 137(7), 561-577. https://doi.org/10.1042/cs20220674

Vancouver

Song G, Weng F, Zou B, Zhao J, Jin J, Yan D, et al. Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway. Clinical Science. 2023;137(7):561-577. doi:10.1042/cs20220674

BibTeX
@article{Song2023,
  author = {Song, Guochao and Weng, Fengyi and Zou, Bin and Zhao, Jing and Jin, Jingyi and Yan, Dongming and Huang, Kai and Sun, Xin and Liu, Chenghai and Hu, Yiyang and Li, Yue and Qiu, Furong},
  title = {Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway},
  journal = {Clinical Science},
  year = {2023},
  volume = {137},
  number = {7},
  pages = {561--577},
  doi = {10.1042/cs20220674}
}
Kostenlos starten →